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a b s t r a c t
Aim: To evaluate the resources and techniques used in the irradiation of patients with
breast cancer after lumpectomy or mastectomy and the status of implementation of new
techniques and therapeutic schedules in our country.
Background: The demand for cancer care has increased among the Spanish population, as
long as cancer treatment innovations have proliferated. Radiation therapy in breast cancer
has evolved exponentially in recent years with the implementation of three-dimensional
conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy and
hypofractionation.
Material and Methods: An original survey questionnaire was sent to institutions participating
in the SEOR-Mama group (GEORM). In total, the standards of practice in 969 patients with
breast cancer after surgery were evaluated.
Results: The response rate was 70% (28/40 centers). In 98.5% of cases 3D conformal treatment
was used. All the institutions employed CT-based planning treatment. Boost was performed
in 56.4% of patients: electrons in 59.8%, photons in 23.7% and HDR brachytherapy in 8.8%.
Fractionation was standard in 93.1% of patients. Supine position was the most frequent.
Only 3 centers used prone position. The common organs of risk delimited were: homolat-
eral lung (80.8%) and heart (80.8%). In 84% histograms were used. An 80.8% of the centers
used isocentric technique. In 62.5% asymmetric ﬁelds were employed. CTV was delimited in
46.2%, PTV in 65% and both in 38.5%. A 65% of the centers checked with portal ﬁlms. IMRTand hypofractionation were used in 1% and in 5.5% respectively.
Conclusion: In most of centers, 3D conformal treatment and CT-based planning treatment
were used. IMRT and hypofractionation are currently poorly implemented in Spain.
© 2012 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.∗ Corresponding author at: Radiation Oncology Department, Hospital de
Tel.: +34 933674144; fax: +34 933674271.
E-mail address: malgara@parcdesalutmar.cat (M. Algara).
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. Background
reast cancer is themost commonnon-cutaneous cancer aris-
ng in women, accounting for nearly one-third of cancers
iagnosed in females. Most cases are diagnosed in post-
enopausal women, with an average age around 60years.
arly detection, when the tumor has not been extended or
hanged, raise the cure rate up to almost 90%. This has also
ncreased the percentage of breast conservative treatment.1
urrently, in Spain, 15.000 new breast cancer cases are diag-
osed each year, indicating that one in sixteen to eighteen
panish women will have breast cancer.2
Adjuvant radiotherapy to the breast is now considered part
f the standard care in breast conserving therapy. An increas-
ng number of women with early breast cancer in Spain and
ther countries are treated with breast-conserving therapy,
ased on the results of trials showing similar efﬁcacy between
hese techniques and mastectomy.3–5 In two meta-analyses,
adiotherapy after breast-conserving therapy was shown to
mprove both locoregional control and survival of patients
ith breast cancer.6 The role of radiotherapy in termsof reduc-
ng local recurrence and increasing survival after conservative
urgery and after a mastectomy has been demonstrated in
everal randomized trials. A meta-analysis published by the
roup of the Early Breast Cancer Trialists’ Collaborative Group
howed that radiation therapy in postoperative loco-regional
reast cancer increases breast cancer survival and overall sur-
ival of patients.7
The demand for cancer care has increased among
he Spanish population, as cancer treatment innovations
ave proliferated. Radiation therapy in breast cancer has
volved exponentially in recent years with the implementa-
ion of three-dimensional conformal radiotherapy (3D-CRT),
ntensity modulated radiotherapy (IMRT), image guided radio-
herapy (IGRT) and hypofractionation. While 3D-CRT has been
onsidered as standard of care, IMRT, IGRT and hypofraction-
tion still need further assessment. To evaluate the state of
he implementation of these new techniques, it is essential
o deﬁne the needs for new units and their characteristics
ince breast cancer represents 25–30% of patients treated in
ost radiotherapy departments in our country.2 Moreover this
tudy is needed prior to the design of multicenter clinical pro-
ocols. There are only a few studies designed to evaluate the
adiation therapy technique used in a daily clinical practice
ancer care in a country, and in Spain there are no studies on
his subject.
A prospective study was proposed by the Breast Cancer
adiation Oncology Spanish Group (GEORM) with the aim to
valuate the resources and techniques used in the irradiation
f patients with breast cancer after lumpectomy or mastec-
omy and the status of implementation of the new techniques
nd therapeutic schedules in our country.
. Materials and methodshe objective of the present study was to collect data from
reatments between February and March 2009, to learn about
he technique and fractionation schedule of radiotherapy intherapy 1 7 ( 2 0 1 2 ) 122–128 123
Spain. For the study to be representative, it was intended to
collect data from 1000 cases in over 28 centers and more than
10 regions of Spain. We designed two tools: a database and a
questionnaire. There was no ﬁnancial support for the present
study.
2.1. Database
A computerized database was developed which included 51
variables (v) allocated into ﬁve groups: demographics (6 v);
characteristics of patients (6 v) and tumors (15 v); other treat-
ments (8 v) and radiotherapy (16 v). Most of these questions
were closed questions, including quantitative and multiple
choice questions. Then, it was sent to departments respon-
sible for breast disease in 40 centers of 12 regions in January
2009. The results were submitted in May 2009. Response was
obtained from 28 centers (70%) of 12 regions of Spain (100%).
2.2. Questionnaire
A questionnaire was designed including 46 v questions about
techniques and aspects related to the positioning of treat-
ment, immobilizing supports (breastboard, braisserie, etc.),
skin references, simulation systems, radiation technique, def-
inition and delineation of GTV and critical organs, dosimetry,
histograms and the control system used in the treatment. The
questions in this surveyweredesigned to learn about radiation
techniques used in breast cancer patients and hence repre-
senting the current Spanish practice. This questionnaire was
ﬁrst tested by 3 experts in the ﬁeld of breast cancer and then
adjusted based on their comments. This questionnaire was
sent to 28 participants, of which 26 (92.9%) responded.
2.3. Statistics
Quantitative and some categorical variables were considered.
Likert scale (categorical variable: never, rarely, sometimes,
very often and always) is a psychometric scale commonly used
in research using surveys. The statistical analysis included
a description of all variables. Intensity factors were calcu-
lated as an average of the responses with the following
numerical categories: (1) never, (2) rarely, (3) sometimes, (4)
very often, and (5) always. The techniques and fractionation
schedules were compared on the basis of previous surgeries,
i.e., lumpectomy and mastectomy.
3. Results
3.1. Patient and tumor characteristics
This study included 969 patients recruited from 28 centers
distributed throughout 12 regions of Spain. The 28 radiation
departments completed a database corresponding to a 70%
response rate and 100% of autonomous communities on the
mailing list. 31.8% of patients came from a screening program.
In total, 25.4%were premenopausal, 7.2%perimenopausal and
66.8% postmenopausal. Patients’ age was 57.8±12.5 years.
Surgical procedures were: 79.3% breast-conserving
surgery (C group) including 52.7% lumpectomy and 26.5%
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Table 1 – Tumor characteristics (%).
Group T0 Tis T1 T2 T3 T4 GI GII GIII N0 N+ RE+ RE− RP+ RP− Her2+ Her2−
28.8
26.4
37.8All 0.6 6.1 51.7 29.7 7.0 4.7 18.7 44.6
C 0.5 7.6 61.3 27.6 2.3 0.7 20.7 46.5
M 1 0.5 14.9 37.8 24.9 20.4 10.9 37.3
quadrantectomy; and 20.7% mastectomy (M group). The most
common histology was inﬁltrating ductal carcinoma (78.9%)
and 6.1% corresponded to intraductal carcinoma. General
characteristics of tumors are shown in Table 1. The T stage
was different between both groups; basically early tumors
were present in the C group and locally advanced in the M
group. Similarly, nodes were positive in 27.4% of the C group
in comparison to 83.4% in the M group.
3.2. Other treatments
These characteristics are shown in Table 2. Neoadjuvant ther-
apywas: 13.5%chemotherapy, 1.3%hormone therapy and0.8%
others or a combination of chemoandhormone therapy. Adju-
vant treatments were: 48.7% chemotherapy, 4.9% hormone
therapy and 8.1% others or combinations. Neoadjuvant treat-
ment was more frequent in the M group (38.8%) than in the C
group (9.1%); however, the sequential or concurrent adjuvant
treatments were similar in both groups. When treatment was
sequential, an interval of 3–4weeks was used. The sentinel
lymph node was performed more frequently in the C group
than in the M group.
3.3. Radiotherapy
Table 3 shows the differences between both groups (C and M).
(1) Position and points of reference: All the centers treated their
patients in the supine position, and only 3 centers occa-
sionally treated in the prone position. Forty-six percent
of centers treated with one arm in an abduction posi-
tion, and in 42% of them with two arms in abduction.
The breastboard was routinely used in 65% of the cen-
ters and only occasionally in 23%. Another type of support
and immobilization was used only in a few centers. Tem-
porary cutaneous brands were used only by 8% of the
centers, whereas the permanent ones were used by 92%.
The majority of the centers used 3 or more brands, usu-
ally 3–4. 73.1% of the centers had their own TC and the rest
used a TC from Radiology Departments.(2) Delineation of organs at risk: The organs of risk delimited
were: homolateral lung (80.8%), contralateral lung (53.8%);
heart (80.8%); headhumeral (23.1%); brachial plexus (3.8%);
contralateral breast (15.4%). In 84%, histograms were used
Table 2 – Other treatments (%).
Group Lymphadenectomy
Sentinel Complete N
All 42.6 52.3 1
C 54.6 41.4
M 4.5 94 360.2 38.7 74.9 20.8 65.4 29.9 17.1 73.3
72 27.4 76.6 19.5 67.7 28.1 15.,4 75.0
14.9 83.4 68.7 25.9 56.7 36.8 23.9 61.2
for the acceptance of treatment, especially in case of
the homolateral lung, using the V20<20%. Delimitation
of critical organs was performed by radiation oncologists
(38.5%), radiotherapists from the Radiotherapy Depart-
ments (15.4%) or medical dosimetrists from the Medical
Physics Departments (19.2%). Dose–volume histograms of
delineated OARs were used to decide on plan acceptance
in relation to speciﬁc criteria in 84% of the responding
institutions.
(3) Volumes delineation: Table 3 shows thedifferences in treated
volumes between both groups (C, M). In 46.2% of the cen-
ters the radiation oncologists delimited theCTV, in 65% the
PTV and in 38.5% both. In 42.3%, the radiopaque surgical
brands were helpful for this procedure. When breast tar-
get volume delineation was performed, various references
and landmarks were used: radiopaque wires visible on CT
were usually used in 61.5% of the centers, and 3.8% never
used them. For the purpose of boost target volume deﬁ-
nition, surgical clips, when available, were used in 42.3%
institutions.
(4) Energy and dosimetry: Most patients were treated with
megavoltage radiation, with 4–6MV photons, generally
6MV. All institutions used CT-based treatment planning.
The most common treatment planning method was the
three-dimensional conformal treatment, both in breast
and in tumor bed. Inverse planning IMRT was performed
only in 1% of the cases. The centers used the isocentric
technique (80.8%) and asymmetric ﬁelds on many occa-
sions (62.5%). A great diversity existed in the number of
ﬁelds of entry to radiate the mammary volume. In 80% of
the occasions more than 2 (segmented ﬁelds) were used.
The irradiation of the supraclavicular nodes was done by
using an anterior ﬁeld in 42% of the cases, adding a pos-
terior one in 19.2% and in association with another type
of ﬁeld in 38.5% of the centers. The boost in tumor bed
was performed in 56.4% of patients and the most com-
monly used delivery method was electrons in 59.8% of
them, followed by photon irradiation in 23.7%, and HDR
brachytherapy in 8.8% of the cases.
(5) Dose and fractionation schedule: Total dose and fractionation
schedule after breast conservative surgery or aftermastec-
tomy was standard in the majority of institutions and for
the majority of patients. The fractionation was different in
the C group, where 5.5% of patients were treated by using
Systemic treatment
eoadjuvant Concomitant Adjuvant
5.6 55.5 71.7
9.1 57 70.8
8.8 60.7 78.1
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Table 3 – Radiotherapy technique.
C group M group
n % n %
768 79.2 201 20.7
Volume Breast 768 100 – –
Chest wall – – 201 100
Supraclavicular 130 16.9 167 83.1
Axila 56 7.3 68 33.8
IMC 21 2.7 6 3
Dosimetry breast or chest wall 2D 2 0.3 – 1.5
3D 758 98.7 – 97.5
IMRT 8 1 0
Energy Cobalt 90 11.7 10 5
4–6MV 643 83.7 160 79.6
>6MV 24 3.1 3 1.5
Electrons – – 22 10.9
Combinations 11 1.4 6 3
Boost Yes 522 68 25 12.4
No 246 32 176 87.6
Dosimetry boost 2D 94 18 7 28
3D 425 81.6 18 72
IMRT 2 0.4 – –
Energy boost Cobalt 40 7.7 – –
Photons 123 23.7 3 12
Electrons 311 59.8 22 88
HDR 46 8.8 – –
Total dose <46Gy 59 7.5 9 4.5
Breast or chest wall 46–50.4Gy 704 91.8 188 93.5
>50.4Gy 3 0.4 4 2
Fraction dose <2Gy 35 4.6 13 6.5
Breast or chest wall 2Gy 675 87.9 180 89.6
2.5–2.67Gy 42 5.5 7 3.5
>5Gy 14 18.2 1 0.5
Total dose boost <10Gy 51 9.7 3 12
10–15Gy 244 46.3 15 60
16–20Gy 174 33 7 28
Fraction dose boost <2Gy 1 0.2 – –
2Gy 422 80.1 22 88
2.3–2.67Gy 7 1.3 2–1 8
3–4.5Gy 46 8.7 1 4
al m
(
(5–10Gy
C group, conservative group; M group, mastectomy group; IMC, intern
the classic hypofractionation schedule and the hypofrac-
tionationwithdoseper fractionof 5 ormoreGywasused in
1.82% of patients. In the M group, hypofractionation tech-
niques accounted for only 4%. Sequential delivery of the
boost for either some or all patients was used in 94% of
the institutions, while a concomitant boost was used in
6% of cases. The most commonly used total boost dose
was 10–16Gy in both groups. However, the doses per frac-
tion were different, 2Gy being the most frequent in both
groups, but the technique in theC grouphypofractionation
accounted for 18.7% (including HDR) compared to only one
case in the M group.
6) Veriﬁcation procedures: The 7.7% of institutions reported to
use X-ray ﬁlm for position veriﬁcation, while 76.9% used
electronic portal imaging device (EPID) and in 3.8% of cases
both X-ray ﬁlm and EPIwere used. Cone beamCTwas used
only in 3.8%. 7.8% of them did not provide data.
7) New technologies/strategies: Speciﬁc questions were added
to identify the use of partial breast irradiation (PBI),46 8.7 – –
ammary chain.
irradiation in the prone position, and breath-hold tech-
niques. PBI was used in one institution, mostly in
selected patients, i.e., patients treated within clinical tri-
als. Irradiation in the prone position is rarely used. None
of the centers did respiratory gating in breast cancer
patients.
4. Discussion
In Spain, in the last decade, cobalt units have been substi-
tutedby linear accelerators at the same time that 2Ddosimetry
has been replaced by the 3D dosimetry. The results of this
survey are based on reports from 28 institutions from 12
regions. In our survey, the response rate to the distributed
questionnaire was 92%, which is higher than similar pre-
vious surveys which reached response rates of 45%, 65%,
41% and 25%, respectively.8–11 The results provide an anal-
ysis of the current practice in the institutions participating
d rad126 reports of practical oncology an
and they give a complete picture of practice across the
country as reﬂected by the number of regions participating
in the survey. As expected, patients who received radia-
tion after conservative treatment had earlier stage of the
disease than those who were treated after mastectomy
(Table 2).
In the present study, the most common therapeutical
method was to treat the patient in the supine position with
one (46%) or two arms (42%) in forced abduction, using
some system of immobilization (65% with breastboard) and
cutaneous permanent brands (92%). In our study, the prone
irradiation position was only occasionally used.
The use of CT has increased rapidly in the last years and
all centers now routinely use CT scans for treatment plan-
ning. A survey in the United Kingdom, performed between
1997 and 1999, showed that only 2 out of 46 institutions used
CT.12 Australian surveys published in 1999, reported that 3 out
of 11 institutions usedCT13 and in 2001 the numbers increased
to 10 out of 20 institutions.8 Another survey reporting on the
period 1998–2002 showed that 66 out of 102 radiation oncology
practices in Australia and New Zealand used CT-based treat-
ment planning.9 The survey in EORTC institutions performed
in 2008–2009 indicates that CT-based planning is now used as
a standard for the delineation of breast target volumes and
organs at risk.14 In the present study, all institutions used CT-
based treatment planning. In our survey, 73.1% of centers had
TC for planiﬁcations and 38.5% used a conventional simulator.
The organs of risk generally delimited are the homolat-
eral lung (80.8%) and the heart (80.8%). Other organs delimited
in a few cases were humeral head, contralateral breast and
braquial plexus. This illustrates that in current clinical prac-
tice, efforts are being made to limit the irradiation dose to
organs at risk, thus reducing the risk of side effects. In 38.5% of
the centers, the delimitation of organs at risk is performed by
radiation oncologists and in the rest by either radiotherapists
(15.4%) or medical dosimetrists (19.2%).
The treatment volumes are different after breast con-
serving treatment than after mastectomy. As expected, the
lymph nodes are included more frequently after mastectomy
(Table 3). However, in Spain it is very rare to include the inter-
nal mammary chain, its radiation being performed only in
cases of sentinel lymph node involvement, so the percent-
age was very similar in both groups. The major differences
among centers were the system for delimitation. Some of
them already delimit CTV and later they do the expansion
to PTV, whereas others continue with the most classic posi-
tion to delimit directly PTV. With regard to the deﬁnition of
clinical target volumes, different methods and procedures are
used by different institutions. The most frequent method is to
use radiopaque wires to delineate the breast target volume.
For delineating the boost target volume surgical clips were
employed.
In spite of the majority of the cobalt units having been
replaced by liner accelerators, 11.7% of conservative and 5% of
post-mastectomy treatments were still performed with these
units. This is due to theneed for optimizationof resources. The
electrons are used only in 10.9% of cases in the irradiation of
the chest wall.
With regard to treatment techniques, wedge ﬁlters are
being replaced by segmentation of ﬁelds. Eighty percent ofiotherapy 1 7 ( 2 0 1 2 ) 122–128
centers used more than two ﬁelds of treatment, 80.8% used
the isocentric technique. In relation to supraclavicular area,
42% of centers normally used one anterior ﬁeld, 19.2% added
a posterior ﬁeld and 38.5% used other ﬁelds. Although previ-
ous studies have demonstrated that IMRT generally improves
dose homogeneity in clinical target volumes, reduces the dose
delivered to normal tissue and limits the incidence of acute
and late skin toxicity and oedema,15–19 it seems that its actual
implementation in clinical practice is still limited. This might
be explained by the fact that the implementation of IMRT may
require additional personnel, special training and dedicated
equipment.
In our survey, the use of electron irradiation was the most
commonmethod used for the boost treatment.Weuse a direct
ﬁeld of electrons in 59.8%, followed by 23.7% by photons and
8.8% with HDR. The variability in the modality of boost treat-
ment among institutions can be probably explained in terms
of comfort for patients, the electrons being the best choice
in this regard, and availability, since not all the services have
HDR units.20 In our study, there were no cases treated with
MammoSite®.21
The predominant dose per fraction size for breast irra-
diation was 2Gy, which was used in 5.5% of treatments in
the C group with a fractionation schedule of 15 fractions of
2.67Gy, which is the same fractionation schedule as that used
in the UK START B trial.22 In the UK START A trial, a dose of
41.6Gy was delivered in 13 fractions,23 while a dose of 42.5Gy
was delivered in 16 fractions in a Canadian trial, which only
included node-negative patients.24 All these trials, including
the updated results of the Canadian trial25 with a median
follow-up of 10year, conﬁrm that hypofractionation is asso-
ciated with excellent local control and toxicity; similar to the
conventional schedule of 50Gy delivered in 2Gy-fractions.
In our country, a 1.8% of cases were treated with weekly
hypofractionation schemes, with fractions greater than or
equal to 5Gy. In the M group, the daily hypofractionation
scheme decreased to 3.5% and the weekly hypofractionation
scheme was only applied in 0.5% of cases weekly. To the boost
it is only givenwithhypofractionation scheme in 1.3%of cases.
Although this survey indicates that hypofractionation is cur-
rently poorly implemented in Spain, it can be expected that
in the near future an increasing number of patients in Spain
will be treated with a higher dose per fraction. Also, the sur-
vey shows that the use of partial breast irradiation is very
unusual; the majority of patients being included in a clinical
trial.
The majority of Spanish institutes apply a sequential boost
with a fraction size for boost irradiation of 2Gy. At the same
time, integrated boost (SIB) is used in a few institutions in
Spain.
76.9% of the institutions reported to use Electronic
Portal Imaging (EPI) for patient set-up veriﬁcation26 and
7.7% used X-ray check. The Cone-Beam is available only
in 3.8% of the centers. There were important differ-
ences in the results from a UK survey published in
2002, when only half of the institutions performed set-
up veriﬁcation.12 The results of EORTC-Radiation Oncology
Group conducted in the years 2008 and 2009 showed
that 92% of the institutions used EPI for patient set-
up.14
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. Conclusions
his survey among the Breast Cancer Radiation Oncology
panish Group indicates that the technique used for treat-
ent of breast cancer with radiotherapy is very homogeneous
n Spain. Broad adoption of new techniques anddevelopments
s in progress.
All responding institutions reported to use CT-based treat-
ent planning. Three-dimensional conformal radiotherapy
nd EPI based patient set-up veriﬁcation are now in main-
tream use, with IMRT techniques being used only in a few
nstitutions. The boost is applied sequentially in the majority
f the responding institutions.
The future is to delegate the delineation of the organs of
isk to technologists, and to increase hypofractionation sched-
les and partial breast irradiation.
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